Wegovy vs Ozempic: Cost, Results, and Which to Choose in 2026

Last updated: May 2026

Medical Disclaimer: This article is educational, not medical advice. Talk to your prescriber about whether semaglutide is appropriate for you.

---

The headline: same molecule, different uses

Wegovy and Ozempic are both semaglutide. Same molecule, same manufacturer (Novo Nordisk), same once-weekly injection. The differences are FDA indication, maximum dose, and price.

Ozempic was approved by the FDA in 2017 for type 2 diabetes. Maximum approved dose: 2.0 mg per week (FDA Ozempic label, 2024).

Wegovy was approved in 2021 for chronic weight management. Maximum approved dose: 2.4 mg per week (FDA Wegovy label, 2024).

That 0.4 mg dose difference matters more than it looks. Weight loss is dose-dependent with semaglutide, and Wegovy's 2.4 mg dose produced significantly more weight loss in head-to-head trial data.

The marketing tells you they're different drugs. The pharmacology says they're the same drug at different ceiling doses.

---

At a glance: Wegovy vs Ozempic

Dimension	Wegovy	Ozempic	Verdict
Active ingredient	Semaglutide	Semaglutide	Identical molecule
FDA indication	Chronic weight management	Type 2 diabetes	Different on-label uses
Maximum dose	2.4 mg/week	2.0 mg/week	Wegovy higher
List price (US, 2026)	$1,349/mo	$968/mo	Ozempic ~28% cheaper
Mean weight loss (68 wk)	14.9% (STEP 1)	6 to 8% off-label	Wegovy 2x more
Insurance coverage	Improving — Medicare 2026, some commercial	Strong if T2D diagnosis	Best for Ozempic
Manufacturer	Novo Nordisk	Novo Nordisk	Same maker
Dose escalation	16 weeks to 2.4 mg	12 weeks to 2.0 mg	Wegovy slower ramp

---

How they work

Both Ozempic and Wegovy are GLP-1 receptor agonists. They mimic glucagon-like peptide-1, a hormone the gut secretes after eating (NEJM STEP 1, 2021).

The mechanism has three parts. They slow gastric emptying, so you feel full longer. They suppress appetite signals in the hypothalamus. And they stimulate glucose-dependent insulin release from the pancreas.

For type 2 diabetes, the insulin and glucose effects matter most. For obesity, the appetite suppression matters most.

That's why the same molecule got two FDA approvals and two brand names.

---

Cost in 2026: the real numbers

Wegovy list price: $1,349 per month at most US pharmacies (Novo Nordisk, 2026).

Ozempic list price: $968 per month (GoodRx, 2026).

Those are cash prices without insurance.

With insurance, both run $25 to $300 per month depending on plan. With a Novo Nordisk patient savings card, commercial-insured patients can pay as little as $0 for Wegovy or $25 for Ozempic, capped at six fills.

Without insurance, the cash market is brutal. Novo Nordisk launched a NovoCare direct-pay program in March 2025 that sells Wegovy for $499 per month in all doses to cash payers — the first major US list price cut on the drug.

Costco's $499/mo program through NovoCare delivers Wegovy directly to home pharmacies without a middleman (NovoCare, 2026). That's still expensive, but it's the lowest legitimate cash price as of May 2026.

For Ozempic, GoodRx coupons can drop the cash price to around $850/mo. Mexican pharmacies sell genuine Novo Nordisk Ozempic for around $250/mo, though importing for personal use is a legal gray area.

---

Compounded semaglutide: the cliff already happened

Compounded semaglutide ran the gray market from 2022 to 2025 at $200 to $400 per month. The FDA removed semaglutide from its drug shortage list in February 2025, and that move ended the legal cover for most 503A compounding (FDA, 2025).

By May 2025, most legitimate telehealth platforms had transitioned off compounded semaglutide and onto brand-name Wegovy or Ozempic. A small number of providers still operate in regulatory gray zones, claiming compounding with "active ingredients" added to semaglutide (B12, glycine).

The FDA has been sending warning letters monthly. Patients shopping for $250/mo compounded semaglutide in 2026 are looking at either expired stockpiles or compounders ignoring the FDA position. Neither is a safe bet.

Real cash-price floor in 2026 for legitimate semaglutide: $499/mo via NovoCare Wegovy. Below that, you're outside the regulated supply chain.

---

Insurance coverage: the deciding factor for most people

Ozempic coverage has been broad since 2017. Most commercial plans cover Ozempic with a type 2 diabetes diagnosis. Medicare Part D covers it for T2D under Standard Formulary Tier 2 or 3 in most plans.

Wegovy coverage has lagged. Medicare did not cover Wegovy for weight loss alone until March 2026, when CMS expanded coverage to patients with established cardiovascular disease under the SELECT trial data (CMS Memo, 2026). Plain obesity without a comorbidity is still not Medicare-covered.

Commercial coverage for Wegovy depends heavily on the employer's pharmacy benefit. Large self-funded employers (Fortune 500, federal government) often cover it. Small employers and high-deductible plans frequently exclude weight-loss drugs.

The fastest test: call the pharmacy benefit number on the back of the insurance card and ask if Wegovy and Ozempic are on the formulary, what tier, and what the prior authorization requires.

For T2D patients, Ozempic is almost always covered. For obesity patients without T2D, Wegovy coverage is a coin flip in 2026.

---

Weight loss results: what the trials show

Wegovy (STEP 1 trial, 2021): Mean weight loss of 14.9% at 68 weeks among 1,961 adults with obesity. Comparator group on lifestyle alone lost 2.4% (NEJM, 2021).

Wegovy (STEP 4 trial, 2022): Patients who maintained the 2.4 mg dose kept losing weight through 68 weeks. Patients who stopped semaglutide and switched to placebo regained two-thirds of lost weight within a year (JAMA, 2022).

Ozempic (SUSTAIN trials, 2017 to 2019): Designed for T2D, not obesity. The 1.0 mg dose produced 4 to 6% weight loss in T2D patients over 56 weeks. The 2.0 mg dose (approved later) produced 6 to 8% weight loss (Lancet, 2021).

Why the gap: Wegovy's 2.4 mg dose is 20% higher than Ozempic's 2.0 mg ceiling. Weight loss is dose-dependent. Patients prescribed Ozempic off-label for weight loss generally cap out below Wegovy's headline number.

For pure weight-loss outcomes, Wegovy wins.

---

Side effects: identical drug, identical side effects

Both drugs have the same FDA-listed adverse events because they're the same molecule.

Common (15 to 44% of patients): nausea, diarrhea, constipation, vomiting, abdominal pain. Most resolve within 8 to 12 weeks as the body adapts.

Less common (1 to 5%): injection-site reactions, fatigue, hair shedding, dehydration, reflux, gallstones.

Black-box warnings: thyroid C-cell tumors in rodents (no confirmed human link). Personal or family history of medullary thyroid cancer or MEN2 is a contraindication (FDA, 2024).

Pancreatitis: rare but listed. Patients with a history of pancreatitis should discuss alternatives.

Gastroparesis: several published case reports in 2024 and 2025 of persistent slow gastric emptying after discontinuation. Mechanism unclear. Persistent vomiting on a GLP-1 needs evaluation.

The slower dose escalation on Wegovy (16 weeks to 2.4 mg vs 12 weeks on Ozempic to 2.0 mg) is designed to reduce GI side effects. In practice, it helps.

---

Cardiovascular and kidney benefits

The SELECT trial (2023) randomized 17,604 overweight or obese adults with established cardiovascular disease to semaglutide 2.4 mg or placebo for an average of 40 months (NEJM SELECT, 2023).

Result: 20% relative reduction in major adverse cardiovascular events (MACE) — heart attack, stroke, cardiovascular death. This is the data that pushed Medicare to expand Wegovy coverage to patients with CVD in March 2026.

The FLOW trial (2024) showed semaglutide reduced kidney disease progression and death by 24% in patients with type 2 diabetes and chronic kidney disease (NEJM FLOW, 2024).

Both effects apply to Ozempic and Wegovy equally because both are semaglutide. The drug does more than weight loss.

---

Which to choose

Have type 2 diabetes? Ozempic. Insurance coverage is strong. The 1.0 mg or 2.0 mg dose handles both glucose control and modest weight loss. If you need more weight loss, talk to your prescriber about adding Wegovy or switching to tirzepatide (Mounjaro or Zepbound).

Obesity without T2D, with insurance that covers Wegovy? Wegovy. The full 2.4 mg dose delivers the headline weight loss. The data is in.

Obesity without T2D, with no Wegovy coverage and $1,349/mo is out of reach? Three options:

• NovoCare $499/mo direct-pay program for Wegovy.
• Ozempic off-label at the 2.0 mg dose, paying out of pocket or via GoodRx. Weight loss will be 6 to 8%, not 14.9%.
• Tirzepatide (Zepbound) often has better commercial coverage and produces 20%+ weight loss at full dose in SURMOUNT-1 (NEJM, 2022).

Have cardiovascular disease history? Either Ozempic or Wegovy. Both reduce MACE 20% based on SELECT data. Medicare will now cover Wegovy in this group.

Worried about the regain after stopping? Plan for indefinite use. STEP 4 showed 60 to 70% weight regain within a year of discontinuation. The drug is a treatment, not a cure.

---

Related Reading

• GLP-1 Diet: What to Eat on Ozempic & Mounjaro
• Semaglutide vs Tirzepatide Comparison
• Best GLP-1 Telehealth Programs 2026

---

Frequently Asked Questions

Is Wegovy literally the same drug as Ozempic?

Yes. Both are semaglutide, manufactured by Novo Nordisk, delivered as a once-weekly subcutaneous injection. The molecule is identical. The FDA indication, maximum dose, and brand packaging differ. Wegovy is approved for chronic weight management at doses up to 2.4 mg per week. Ozempic is approved for type 2 diabetes at doses up to 2.0 mg per week (FDA Wegovy label, 2024).

Why is Wegovy more expensive than Ozempic if it's the same drug?

Two reasons. Wegovy's higher 2.4 mg dose costs slightly more to produce per pen. And Novo Nordisk prices the obesity indication higher because the patient population is larger and insurance leverage is weaker than in T2D. The pricing reflects market segmentation, not chemistry. The actual cost of goods difference is small.

Can I take Ozempic for weight loss if I don't have diabetes?

Many prescribers do this off-label, and it's legal. Insurance typically won't cover Ozempic without a T2D diagnosis, so most off-label users pay cash or use GoodRx coupons. Weight loss at the 2.0 mg off-label dose averages 6 to 8% over a year, less than Wegovy's 14.9%. If insurance won't cover Wegovy and the goal is weight loss, off-label Ozempic is a reasonable but lower-ceiling option (Lancet, 2021).

Does Medicare cover Wegovy in 2026?

Partially. As of March 2026, CMS covers Wegovy for Medicare patients with established cardiovascular disease, based on the SELECT trial data showing 20% MACE reduction (CMS Memo, 2026). Medicare does not yet cover Wegovy for obesity alone — the patient needs an additional qualifying condition (CVD, prior heart attack, prior stroke). Coverage policy is expected to expand further over 2026 to 2027 as more outcomes data emerges.

Will I regain weight if I stop Wegovy or Ozempic?

Most patients do. The STEP 4 trial found that patients who stopped semaglutide and switched to placebo regained about two-thirds of their lost weight within a year (JAMA, 2022). The mechanism: appetite returns, gastric emptying speeds back up, and the metabolic adaptation to weight loss persists. Maintaining loss after discontinuation requires aggressive lifestyle change — high protein, resistance training, calorie awareness. Most clinicians now plan for indefinite use, with off-ramps reserved for patients hitting goal weight and willing to commit to maintenance protocols.

---

-- The GLP-1 Daily Team